Corvus Pharmaceuticals(CRVS) Newsfilter·2024-12-17 21:01Core Insights - Corvus Pharmaceuticals will announce interim data from a Phase 1 clinical trial of soquelitinib for atopic dermatitis on December 18, 2024 [1] - A conference call and webcast will be held to discuss the clinical data, accessible via phone and the company's website [2] About Soquelitinib - Soquelitinib is an investigational oral small molecule drug that selectively inhibits ITK, impacting T cell differentiation and immune function [3] - The drug has shown potential in treating cancers and autoimmune diseases by shifting T cell differentiation towards regulatory cells [3] - A registrational Phase 3 trial for relapsed peripheral T cell lymphoma has been initiated based on positive Phase 1/1b results [3] About Corvus Pharmaceuticals - Corvus Pharmaceuticals is focused on developing ITK inhibition as a novel immunotherapy approach for various cancers and immune diseases [4] - The company’s lead candidate is soquelitinib, with other clinical-stage candidates targeting different cancer indications [4]